Press Program 2024
PRESS CONFERENCE 1: SUNDAY, APRIL 7, 2024
AACR Annual Meeting Clinical Trials Committee Cochair Shivaani Kummar, MD, Oregon Health & Science University Knight Cancer Institute, moderated the press conference.
The following studies were presented:
Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status
Presented by Jiafu Ji, MD, PhD, DrPh, Peking University Cancer Hospital & Institute in Beijing
Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate with Clinical Benefit
Presented by Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center
Accelerated Aging May Increase the Risk of Early-onset Cancers in Younger Generations
Presented by Ruiyi Tian, MPH, Washington University School of Medicine in St. Louis
Fewer Than Half of Accelerated Approval Drugs Showed Clinical Benefit in Confirmatory Trials After Five Years
Presented by Edward Cliff, MBBS, MPH, Brigham and Women’s Hospital and Harvard Medical School
PRESS CONFERENCE 2: Monday, April 8, 2024
AACR Annual Meeting Clinical Trials Committee Cochair Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital, moderated the press conference.
The following studies were presented:
Adagrasib Plus Cetuximab May Provide Clinical Benefit in Patients With KRASG12C-mutated Colorectal Cancer
Presented by Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center
Next-generation PARP Inhibitor Demonstrates Clinical Benefit in Patients with Homologous Recombination Repair-deficient Breast Cancer
Presented by Timothy A. Yap, MBBS, PhD, The University of Texas MD Anderson Cancer Center
An Exosome-based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer
Presented by Ajay Goel, PhD, City of Hope
PRESS CONFERENCE 3: Tuesday, April 9, 2024
Roy S. Herbst, MD, PhD, Yale Cancer Center, moderated the press conference.
The following studies were presented:
Artificial Intelligence Analysis of DNA Fragmentomes and Protein Biomarkers Noninvasively Detects Ovarian Cancer
Victor Velculescu, MD, PhD, FAACR, Johns Hopkins Kimmel Cancer Center
AZD1390 With Radiotherapy Shows Manageable Safety Profile and Preliminary Efficacy for Patients with Glioblastoma in Phase I Trial
Jonathan T. Yang, MD, PhD of Memorial Sloan Kettering Cancer Center
Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients with Resected Head and Neck Cancers
Olivier Lantz, MD, PhD, Institut Curie in Paris.
aDDITIONAL NEWS RELEASES
A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer
Presented by Charles Link, MD, Lankenau Institute for Medical Research, part of Main Line Health
Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Patients with African and European Ancestries
Shyh-Han Tan, PhD, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation
Culturally Sensitive Video Targeting Black Men May Help Increase Awareness About Prostate Cancer
Mallorie C. Jones, MA, Perelman School of Medicine at the University of Pennsylvania